Autoimmunity reviews最新文献

{"title":"Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases - a systematic review.","authors":"Mads Bundgaard Nielsen, Rikke Helin Johnsen, Jann Mortensen, Saher Burhan Shaker, Christoffer Tandrup Holst Nielsen","doi":"10.1016/j.autrev.2025.103856","DOIUrl":"https://doi.org/10.1016/j.autrev.2025.103856","url":null,"abstract":"<p><strong>Background: </strong>Currently, no tools can monitor ongoing fibrotic activity properly, making early identification of and timely therapeutic intervention with antifibrotics in patients with progressive fibrosing interstitial lung disease (ILD) difficult. Fibroblast activation protein-α inhibitor (FAPI) radiotracers could address these challenges.</p><p><strong>Objective: </strong>This review examines the association between pulmonary FAPI tracer uptake, fibrotic activity, and clinical parameters used for disease monitoring and prognostication in ILD to provide insights into its clinical potential.</p><p><strong>Methods: </strong>In January 2025, a systematic literature search on PubMed, Ovid Medline, and Cochrane Library, utilizing the block-search strategy and snowballing, was conducted, and 13 studies were included.</p><p><strong>Results: </strong>Both murine and human studies support that FAPI tracer uptake reflects fibrotic activity in ILDs, as uptake was consistently elevated in subject groups compared to controls. In murine ILD models, increased uptake was associated with fibrosis and fibroblast activation protein-α (FAP-α) expression upon histological examination. Uptake preceded the development of fibrosis on computed tomography (CT) and attenuated once fibrosis was established. In human ILD patients (Idiopathic pulmonary fibrosis (IPF) = 55, Connective tissue disease (CTD) ILD = 68, other ILDs = 55), FAPI uptake was localized to fibrotic lesions on high-resolution computed tomography (HRCT) and associated with increased FAP-α expression ex vivo. Uptake correlated with baseline pulmonary function tests (PFTs) and fibrosis extent on HRCT. Increased FAPI tracer uptake at baseline predicted disease progression upon follow-up.</p><p><strong>Conclusion: </strong>An increasing body of evidence supports that FAPI tracers hold great clinical potential for the management of ILD by accurately monitoring fibrotic disease activity and identifying patients at risk of progression. Further research is required to confirm these findings.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103856"},"PeriodicalIF":9.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium.","authors":"Otavio Cabral-Marques, Lena F Schimke, Guido Moll, Igor Salerno Filgueiras, Adriel Leal Nóbile, Anny Silva Adri, Fernando Yuri Nery do Vale, Júlia Nakanishi Usuda, Yohan Lucas Gonçalves Corrêa, Débora Albuquerque, Roseane Galdioli Nava, Ronaldy Santana Santos, Haroldo Dutra Dias, Hélio Fernandes Silva, Pedro Batista Marconi, Rusan Catar, Michael Adu-Gyamfi, Pinchao Wang, Taj Ali Khan, Alexander M Hackel, Anja Leheis, Anja Stähle, Antje Müller, Carolin Schmidt, Chiara Radunovic, El-Baraa Adjailia, Hanna Grasshoff, Jens Y Humrich, Jonas Menz, Konstantinos Fourlakis, Maike Winziers, Maj Jäpel, Manuel Vincent Wegner, Peter Lamprecht, Relana Nieberding, Reza Akbarzadeh, Sabrina Arnold, Sebastian Jendrek, Sebastian Klapa, Solveig Augustin, Sophie Biedermann, Susanne Schinke, Patrick Scheerer, Matthias Endres, Kai Schulze-Forster, Friedemann Paul, Xinhua Yu, Franziska Sotzny, Thomas P Sakmar, Miroslaw Banasik, Aiden Haghikia, Markus H Hoffmann, Dmitry Veprintsev, Torsten Witte, Rodrigo J S Dalmolin, Hans D Ochs, Harald Heidecke, Carmen Scheibenbogen, Yehuda Shoenfeld, Gabriela Riemekasten","doi":"10.1016/j.autrev.2025.103855","DOIUrl":"https://doi.org/10.1016/j.autrev.2025.103855","url":null,"abstract":"<p><p>The 5th International Symposium on Regulatory Autoantibodies Targeting GPCR (RAB-GPCRs) advanced the understanding of the significant role played by autoantibodies targeting G-protein-coupled receptors (GPCRs) in various human diseases. Once considered passive markers, RAB-GPCRs are now recognized as active modulators of cellular signaling, immune regulation, and inflammation. The symposium highlighted their involvement in multiple prominent pathologies, including autoimmune diseases, cardio- and cerebrovascular diseases, and neuroimmunologic disorders such as myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 syndrome (ME/CFS/PCS), as well as solid organ and hematopoietic stem cell transplantation (SOT/HSCT). Experts from rheumatology, immunology, and neurology presented interdisciplinary discussions on the potential of RAB-GPCRs as biomarkers and therapeutic targets. Advances in screening methods, biomarker identification, and therapeutic strategies were shared, emphasizing their diagnostic potential and application in novel therapeutic interventions. This report summarizes key insights from the symposium, particularly focusing on the modulatory properties of RAB-GPCRs and their relevance in both immune-mediated diseases and other pathologies (e.g., vascular, degenerative) that are traditionally not considered primarily immune-mediated. Ongoing research is expected to further establish these autoantibodies as crucial components in disease modulation and systems biology contexts, offering new opportunities for precision medicine and improved clinical outcomes in immune-related disorders.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103855"},"PeriodicalIF":9.2,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic evaluation of the associations between schizophrenia and autoimmune diseases: An umbrella review","authors":"Zhouyang Sun,&nbsp;Beibei Han,&nbsp;Qianlu Ding,&nbsp;Yuan Feng,&nbsp;Tingyi Jia,&nbsp;Yixin Ouyang,&nbsp;Xinru Guo,&nbsp;Jingyi Liang,&nbsp;Qianlong Huang,&nbsp;Changgui Kou ,&nbsp;Wei Bai","doi":"10.1016/j.autrev.2025.103854","DOIUrl":"10.1016/j.autrev.2025.103854","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess research trends in the association between schizophrenia and autoimmune diseases, systematically review their relationship, and evaluate the credibility of existing evidence.</div></div><div><h3>Methods</h3><div>Bibliometric analysis was conducted using the bibliometrix package in R, along with VOSviewer and CiteSpace. Relevant systematic reviews and meta-analyses were retrieved from six databases: PubMed, Web of Science, Embase, CINAHL, PsycINFO, and the Cochrane Library. Summary risk estimates were recalculated using the DerSimonian and Laird method under a random-effects model, and the credibility of the evidence was assessed.</div></div><div><h3>Results</h3><div>The bibliometric analysis found that “meta-analysis” has become a frequently used keyword and may be a focal point for future research. The umbrella review included 17 articles, containing 24 report data points from 12 quantitative reviews. Results indicated that 9 reports assessed the relationship between schizophrenia and autoimmune diseases. Schizophrenia was significantly associated with autoimmune neurological disorders <em>(RR</em> = 1.42; 95 % <em>CI</em> = 1.18–1.72), providing suggestive evidence. Seven reports evaluated the impact of schizophrenia on autoimmune diseases, showing highly suggestive evidence that schizophrenia patients had a pooled relative risk of 2.22 (95 % <em>CI</em> = 1.95–2.52) for psoriasis. Eight reports assessed the impact of autoimmune diseases on schizophrenia, with bullous pemphigoid patients showing significantly higher schizophrenia prevalence (<em>OR</em> = 2.63; 95 % <em>CI</em> = 2.03–3.39).</div></div><div><h3>Conclusions</h3><div>This study synthesizes evidence of varying levels, highlighting the association between schizophrenia and autoimmune diseases. It offers new insights for future exploration, fosters interdisciplinary collaboration, and provides valuable implications for public health policy development.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103854"},"PeriodicalIF":9.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features, pathogenesis, and treatment of inflammatory bowel disease-associated spondyloarthritis","authors":"Mitsuhiro Akiyama,&nbsp;Waleed Alshehri,&nbsp;Koji Suzuki,&nbsp;Kanako Shimanuki,&nbsp;Koichi Saito,&nbsp;Yuko Kaneko","doi":"10.1016/j.autrev.2025.103853","DOIUrl":"10.1016/j.autrev.2025.103853","url":null,"abstract":"<div><div>Inflammatory bowel disease-associated spondyloarthritis (IBD-SpA) is a unique subtype of SpA that affects approximately 10–20 % of patients with IBD. It encompasses both peripheral arthritis and axial involvement, with enthesitis being increasingly recognized. Despite its clinical significance, there are currently no established screening tools, classification criteria, or standardized treatment guidelines specific to IBD-SpA. Management is typically guided by recommendations for IBD and SpA, requiring close collaboration between gastroenterologists and rheumatologists. Emerging evidence suggests that subclinical gut inflammation and IL-23–IL-17–TNFα signaling pathway play central roles in the pathogenesis of IBD-SpA. Among the available therapeutic options, TNF inhibitors and JAK inhibitors have demonstrated efficacy in both IBD and SpA, whereas IL-17 inhibitors may exacerbate intestinal inflammation. Additionally, vedolizumab, an α4β7 integrin inhibitor, while effective for IBD, has been implicated in triggering de novo SpA. These complexities highlight the need for a tailored treatment approach that balances efficacy for both gut and joint inflammation. This review provides an updated overview of the clinical features, diagnosis, pathogenesis, and treatment strategies for IBD-SpA, emphasizing recent advancements and future directions in the field.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103853"},"PeriodicalIF":9.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoreactive B cells in autoimmune diseases: Mechanisms, functions and clinical implications","authors":"Aurore Collet ,&nbsp;Thomas Guerrier ,&nbsp;Sébastien Sanges ,&nbsp;Aurélien Chépy ,&nbsp;Vincent Sobanski ,&nbsp;David Launay ,&nbsp;Sylvain Dubucquoi","doi":"10.1016/j.autrev.2025.103851","DOIUrl":"10.1016/j.autrev.2025.103851","url":null,"abstract":"<div><div>Autoreactive B cells play a key role in the pathophysiology of autoimmune diseases (AIDs). Still, due to their low frequency in the circulating blood, they are less well characterized than the global B cell pool. This review aims at describing the tools that allow the study of autoreactive B cells, deciphering their features and functions, and discussing the therapeutic implications that arise from these findings.</div><div>The capacity to detect and analyze autoreactive B cells has been significantly improved by diverse techniques such as ELISpot and flow cytometry, shedding light on their roles in immune dysregulation. It reveals the multifaceted features of autoreactive B cells in terms of phenotypic and functional characteristics, that vary between different AIDs, and from one autoantigen to another. This heterogeneity may be influenced by factors such as the nature of the targeted autoantigen, or the costimulatory signals involved. These observations highlight that autoreactive B cells contribute not only to autoantibody production, but also to the perpetuation of autoimmunity through additional mechanisms, including antigen presentation and cytokine secretion. Recent therapeutic approaches have been developed to target autoreactive B cells, allowing an antigen-specific depletion of B cells, without causing widespread immunosuppression. Challenges remain, such as understanding the precise mechanisms by which the B cell tolerance breakdown occur, and the pathways by which autoreactive B cells activate (i.e. germinal centre or extrafollicular pathway). Ongoing research into the mechanisms regulating autoreactive B cells will be crucial for designing more targeted and effective therapies, leading to better outcomes for AID patients.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 8","pages":"Article 103851"},"PeriodicalIF":9.2,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of B cells in Sjögren's syndrome and their impact on the nervous system","authors":"Chuanxin Su ,&nbsp;Wang Wang ,&nbsp;Fang Cheng ,&nbsp;Futao Zhao ,&nbsp;Song Guo Zheng","doi":"10.1016/j.autrev.2025.103852","DOIUrl":"10.1016/j.autrev.2025.103852","url":null,"abstract":"<div><div>Primary Sjögren's syndrome is an autoimmune disease characterized by the dryness of exocrine glands. Recent studies emphasizes the significant role of B cells in its pathogenesis. This review provides an overview of the functions of B cells in Sjögren's syndrome and their impact on the nervous system. Current studies on the association between B cell-mediated immune responses and neurological symptoms are reviewed, aiming to offer new insights for diagnosing and treating. Understanding these connections is crucial for addressing the complex interplay between the immune system and neurological manifestations in affected individuals. A critical gap remains in determining whether B cell dysregulation initiates neuropathology or amplifies pre-existing neural inflammation, highlighting the need for mechanistic studies to guide targeted therapies.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 8","pages":"Article 103852"},"PeriodicalIF":9.2,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Safety of biologics in patients with autoimmune rheumatic diseases during pregnancy: Systematic review and meta-analysis” [Autoimmunity Reviews, Volume 24 (2025), Issue 8, /103827]","authors":"Shiran Li ,&nbsp;Hongxi Liu ,&nbsp;Siyu Zeng ,&nbsp;Jingxian Xie ,&nbsp;Zhimin Li ,&nbsp;Yong Yang ,&nbsp;Junlan Chuan","doi":"10.1016/j.autrev.2025.103840","DOIUrl":"10.1016/j.autrev.2025.103840","url":null,"abstract":"","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 8","pages":"Article 103840"},"PeriodicalIF":9.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clostridioides difficile-related reactive arthritis: A scoping review of the literature","authors":"Dimitrios Deligeorgakis ,&nbsp;Evangelia S. Makri ,&nbsp;Konstantinos Tsafis ,&nbsp;Elpida Skouvaklidou ,&nbsp;Ioanna Katsigianni ,&nbsp;Christina Adamichou ,&nbsp;Nikolaos Kougkas ,&nbsp;Theodoros Dimitroulas","doi":"10.1016/j.autrev.2025.103842","DOIUrl":"10.1016/j.autrev.2025.103842","url":null,"abstract":"<div><div>Reactive arthritis (ReA) is an inflammatory arthritis triggered by preceding infection. While various bacterial pathogens are well-established as causative agents, the role of <em>Clostridioides difficile</em> remains less elucidated. Α scoping review was conducted to evaluate the existing literature on CDI-induced ReA to determine clinical features, management, and disease trajectory. Sixty-one CDI-related ReA cases were identified (61 % male, mean age 38.8 years). HLA-B27 positivity was 64 % (30/47 tested). Prior antibiotic use was reported in 89 % of cases, with arthritis onset 8.5 days post-CDI. Oligoarthritis predominated (41 %), involving a median of 3 joints (knee 67 %, ankle 44 %, hand 26 %). Extra-articular manifestations were present in 20 %. Only 10 % required treatment escalation to disease-modifying anti-rheumatic drugs (DMARDs). Remission was achieved in 87 % within 21 days, with 9 % relapse rate. HLA-B27 positive patients had fewer affected joints (2 <em>vs</em> 5, <em>p</em> = 0.03) and older age at onset (43.1 <em>vs</em> 29.1, <em>p</em> = 0.02). Pediatric patients were more likely to experience hip arthritis than adults (54 % <em>vs</em> 10 %, <em>p</em> = 0.003). This study confirms CDI as a cause of ReA, highlighting its typically benign course with high remission rates. Further research is warranted, particularly regarding refractory cases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 8","pages":"Article 103842"},"PeriodicalIF":9.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and immune dysregulation in vitiligo: Insights into autoimmune mechanisms and disease pathogenesis","authors":"Sathvik Upadhya ,&nbsp;Melisa J Andrade ,&nbsp;Vaibhav Shukla ,&nbsp;Raghavendra Rao ,&nbsp;Kapaettu Satyamoorthy","doi":"10.1016/j.autrev.2025.103841","DOIUrl":"10.1016/j.autrev.2025.103841","url":null,"abstract":"<div><div>Vitiligo is a hypopigmentary skin disease condition affecting local melanocytes leading to the white patched/macules of depigmented skin due to their progressive loss of melanocytes in the epidermis. Vitiligo pathogenesis involves complex interaction of several trigger factors including genetic predispositions, environmental stimuli, oxidative stress, immunological dysregulation, and impaired melanocyte function. Genetic studies have provided insight into the essential aspects related to immunological modulation, melanocyte biology and the oxidative stress response, aiding in understanding the possible mechanisms underlying vitiligo susceptibility. Epigenetic modifications further contribute to the regulatory landscape controlling the pathophysiology of this disease. While genetic studies identified key susceptibility loci, it is the functional studies that have driven the development of novel targeted therapies. Although vitiligo exhibits complex heterogenous clinical manifestations and multiple contributing factors, significant advancements have been achieved in understanding the underlying mechanism of the disease. Particularly, cytotoxic T-cell activity and interferon-gamma (IFN-ϒ) mediated immune response have been studied extensively in disease pathogenesis. This has led to the development of novel targeted therapies including cytokine targeted therapies, Janus-activated kinase (JAK) signaling inhibitors, and Wnt signaling agonists which have shown potential clinical success.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 8","pages":"Article 103841"},"PeriodicalIF":9.2,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease","authors":"Thorben Witte ,&nbsp;Ioanna Minopoulou ,&nbsp;Norman Michael Drzeniek ,&nbsp;Murat Torgutalp ,&nbsp;Robert Sabat ,&nbsp;Vincent Casteleyn ,&nbsp;Fredrik Albach ,&nbsp;Filippo Fagni ,&nbsp;Georg Schett ,&nbsp;Alen Zabotti ,&nbsp;Gerhard Krönke ,&nbsp;Dennis McGonagle ,&nbsp;Michaela Köhm ,&nbsp;Frank Behrens ,&nbsp;Arnd Kleyer ,&nbsp;David Simon","doi":"10.1016/j.autrev.2025.103839","DOIUrl":"10.1016/j.autrev.2025.103839","url":null,"abstract":"<div><div>Psoriatic disease, encompassing psoriasis (PsO) and psoriatic arthritis (PsA), affects approximately 2 % of the global population. In the majority of cases, skin alterations occur first, followed by musculoskeletal disorders. The transition from cutaneous to synovio-entheseal disease reflects a gradual immune-driven progression from localized to systemic manifestations in most cases. Subclinical or non-specific symptoms often precede demonstrable synovitis or enthesitis, which further delays diagnosis and increases the risk of irreversible structural damage. Despite the critical importance of early detection, established risk factors for PsA are largely nonspecific, presenting challenges for precision medicine. Key amongst these is the presence of arthralgia, which usually precedes PsA development but is also common in degenerative and biomechanical problems. Recent advancements, encompassing cutting-edge imaging modalities, hold the potential to facilitate earlier and more precise detection of PsA, while groundbreaking therapeutic innovations are redefining treatment paradigms and may further integrate advanced imaging into personalized therapeutic strategies. This review explores the molecular and clinical complexity of psoriatic disease, highlights the latest developments in imaging and treatment, and considers their potential to revolutionize patient outcomes. Novel strategies promise advances in precision medicine and may pave the way for customized interventions that not only enhance the diagnosis and prognosis of psoriatic disease but also refine therapeutic decision-making. Innovative imaging techniques are essential to distinguishing psoriatic disease-related pain from alternative causes such as osteoarthritis, thereby guiding treatment continuation and optimization.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 8","pages":"Article 103839"},"PeriodicalIF":9.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}